spacer
home > pmps > summer 2019 > the promise of connected health
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Promise of Connected Health

It is a known fact that measuring medication effectiveness and adherence plays an important role in managing and improving patient health. However, pharmaceutical companies struggle with procuring data that shows when, or even if, patients take their medication. A range of research has demonstrated that up to 50% of all medicines are not taken as prescribed (1). Even for patients with chronic conditions, adherence is only 50-60% (2).

These statistics are pretty eye-opening when it comes to patient health outcomes, but the news also has a negative financial impact for pharma manufacturers as medication nonadherence accounts for approximately $188 billion in lost revenue (3). Taking an even closer look, adherence rates ranging from 31-66% for popular respiratory, diabetes, and autoimmune drugs can leave between $1 billion and $10 billion ‘on the table’ in any given year (4). However, even as little as a 3% increase in adherence can generate more than $1 to $3 billion in additional revenue for these popular drugs over a five-year period. This is significant, especially as the cost of new prescription drug development can be as high as $2.6 billion (5). Despite this investment, even if patients fill their prescription, whether or not they actually take the medication cannot be guaranteed. Connected health solutions can help close this gap.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kevin Deane is Vice President of Innovation at Phillips-Medisize. With over 25 years of experience developing new products, Kevin has supported a broad range of drug delivery and medical devices to market. He leads an early-stage development team and coordinates large-scale developments in connected health, from devices to data, pulling together the deep capabilities across Phillips-Medisize and Molex. Kevin moved from the US to Cambridge, UK, in 1994 and worked for PA Consulting as a Partner in the Technology Group. He has led a number of drug delivery and connected health projects for pharma clients across Europe, Asia Pacific, and the US, supporting strategic assessment through to full system implementations.
spacer
Kevin Deane
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

White Papers
 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement